RSV in Babies

Reviewed by Ann Dietrich, MD, FAAP, FACEP 

Key Takeaways

Respiratory syncytial virus (RSV) is a major cause of infant respiratory morbidity and, before the introduction of preventive immunizations, was the leading cause of infant hospitalization in the United States. In babies, RSV often begins with nonspecific upper respiratory symptoms but can progress over several days to bronchiolitis, feeding difficulty, apnea, hypoxemia, and respiratory distress. The highest-risk infants include very young babies, especially those in their first RSV season, as well as infants born prematurely and those with underlying cardiopulmonary or immunologic vulnerability.  

Diagnostic confirmation is not necessary in every outpatient case, but molecular testing can be useful when results will affect management, cohorting, or diagnostic clarity. Treatment for most infants remains supportive, with escalation based on hydration status, work of breathing, oxygenation, and apnea risk.  

Prevention has changed the infant RSV landscape. The Centers for Disease Control and Prevention (CDC) recommends that all infants be protected against severe RSV either through maternal RSV vaccination during pregnancy or infant immunization with a long-acting monoclonal antibody. Most infants do not need both.  

Introduction

RSV is one of the most clinically significant viral respiratory pathogens in infancy. Although many infections are mild and self-limited, RSV remains a leading driver of bronchiolitis, emergency visits, and hospitalization in the first year of life. The CDC notes that RSV can be dangerous for infants and some young children and that, before RSV immunizations became available, it was the leading cause of infant hospitalization in the United States.  

For clinicians, RSV in babies is important not only because of its frequency, but because the disease can worsen after an apparently mild start. The infant with rhinorrhea and a mild cough on day 1 may present on day 3 or 4 with poor feeding, tachypnea, retractions, or apnea. That staged progression is one of the defining counseling points for families.  

Why RSV matters in babies

RSV usually causes mild, cold-like illness in most people, but infants are disproportionately affected by severe disease. Babies can develop bronchiolitis and pneumonia, and clinical severity may be amplified by small airway caliber, limited respiratory reserve, immature feeding endurance, and vulnerability to dehydration. The CDC identifies infants among the groups most likely to develop severe RSV illness.  

The burden is not evenly distributed across infancy. Very young infants, especially those younger than 6 months of age, are at particularly high risk of hospitalization, and presentation in the youngest infants may be subtle. Rather than obvious wheezing at first, clinicians may see decreased activity, irritability, poor feeding, or apnea.  

Clinical presentation in babies

In babies, RSV often begins with rhinorrhea, congestion, decreased appetite, and cough. Symptoms usually appear four to six days after infection. Unlike influenza, RSV symptoms may emerge in stages rather than all at once.  

As the illness progresses, infants may develop wheezing, tachypnea, nasal flaring, retractions, grunting, hypoxemia, or apnea. The CDC notes that very young infants may show irritability, decreased activity, and breathing difficulties, and some infants may not have fever. This matters clinically because the absence of fever does not exclude significant lower respiratory tract disease in a young baby.  

For bedside assessment, feeding is often as important as auscultation. An infant with modest wheeze but worsening oral intake, fewer wet diapers, or fatigue with feeds may be at greater immediate risk than the exam alone suggests. That is especially true in the several-day window when symptoms intensify.  

Which babies are at highest risk?

RSV can be serious in any infant, but the risk of severe disease is higher in babies who are very young, born prematurely, or have chronic lung disease, congenital heart disease, or weakened immune systems. The CDC also emphasizes that all infants should be protected against severe RSV disease through maternal vaccination or infant monoclonal antibody immunization.  

Risk stratification should influence both counseling and disposition. A thriving older infant with mild congestion may be managed expectantly, while a younger infant in the first months of life with declining intake or increased work of breathing warrants a lower threshold for in-person reassessment. That clinical approach is an inference supported by the CDC’s identification of infancy as a high-risk period and its emphasis on breathing difficulty and dehydration-related concerns.  

Diagnostic approach in babies

RSV cannot be reliably distinguished from other viral respiratory illnesses based on symptoms alone. CDC states that RSV symptoms are nonspecific and overlap with other viral infections and some bacterial infections. Laboratory confirmation is most useful when it will affect management, infection control, cohorting, or diagnostic certainty.  

The most commonly used RSV tests are nucleic acid amplification tests (NAATs), including polymerase chain reaction (PCR)-based assays, and antigen tests. NAATs are highly sensitive, while antigen tests are faster but generally less sensitive. In hospital, emergency, and high-risk ambulatory settings, multiplex molecular testing may be particularly useful when influenza, SARS-CoV-2, and RSV are circulating together.  

Not every infant with suspected RSV needs testing. In a clinically stable outpatient whose management will remain supportive regardless of the result, confirmatory testing may add little. In contrast, testing may be more useful in hospitalized infants, infants needing cohorting, or cases in which ruling in RSV helps narrow the differential.  

Treatment of RSV in babies

Treatment for most babies with RSV is supportive. The CDC states that most RSV infections go away on their own and that symptoms can often be managed supportively. In infant practice, this generally means close attention to hydration, secretion management, feeding tolerance, respiratory effort, and oxygenation.  

Escalation of care should occur for apnea, persistent hypoxemia, moderate to severe work of breathing, exhaustion, inability to maintain hydration, or concern for clinical deterioration. Babies often worsen after several days of illness, so families should be counseled that a seemingly mild day 1 presentation does not guarantee a mild overall course.  

In inpatient care, management is still primarily supportive. The central goals are maintaining oxygenation, supporting hydration and feeding, and monitoring for progression. The CDC’s public guidance does not recommend a routine virus-specific outpatient treatment for RSV; the mainstay remains supportive care rather than targeted antiviral therapy.  

Transmission and household spread

RSV is contagious and spreads through respiratory droplets, direct contact, and contaminated surfaces. People with RSV are usually contagious for three to eight days, but some infants can continue to spread the virus for four weeks or longer.  

This prolonged shedding in some infants has practical implications for households, day care settings, and contact with medically fragile relatives. Clinicians should counsel families that contagiousness may outlast the period of peak visible illness in babies. That conclusion is supported by the CDC’s transmission guidance and prolonged infant shedding information reflected in its RSV clinical content.  

Prevention in babies

Prevention is now central to infant RSV care. The CDC recommends that all infants be protected against severe RSV disease through one of two approaches: maternal RSV vaccination during pregnancy or infant immunization with a long-acting monoclonal antibody. Most infants do not need both.  

The CDC states that the maternal RSV vaccine, Pfizer’s Abrysvo, is given at 32 through 36 weeks of pregnancy and that the transferred maternal antibodies protect the infant for about six months after birth. The CDC also states that long-acting infant antibodies such as nirsevimab or clesrovimab provide immediate protection and last at least 5 months.  

For infants younger than 8 months of age entering their first RSV season, nirsevimab is recommended when the mother did not receive RSV vaccine during pregnancy, the maternal vaccination status is unknown, or the infant was born within 14 days of maternal vaccination. Some children 8 through 19 months of age who are at increased risk may also be eligible entering their second RSV season.  

Clinical bottom line

RSV in babies should be approached as a common but potentially serious infant respiratory infection. Many babies recover with supportive care alone, but clinicians must remain alert to the characteristic pattern of worsening several days into the illness, especially when feeding declines or work of breathing rises. Diagnostic testing is selective rather than universal, supportive care remains the mainstay of treatment, and prevention through maternal vaccination or infant monoclonal antibody protection is now a core part of infant RSV management.  

FAQ

How serious is RSV in babies?

RSV can be mild, but it can also be serious in infants and is a major cause of infant hospitalization. Babies are at risk for bronchiolitis, pneumonia, feeding difficulty, dehydration, apnea, and respiratory distress.  

What are the first signs of RSV in a baby?

Early signs usually include runny nose, congestion, decreased appetite, and cough. In very young infants, symptoms may be more subtle and include irritability, decreased activity, poor feeding, or apnea.  

How is RSV treated in babies?

Most infants are treated with supportive care. Management focuses on hydration, feeding tolerance, secretion management, and monitoring breathing and oxygenation rather than a routine virus-specific medication.  

When should a baby with RSV be evaluated urgently?

Urgent evaluation is appropriate for apnea, cyanosis, increasing work of breathing, retractions, nasal flaring, poor feeding, signs of dehydration, lethargy, or worsening symptoms over several days..  

Should babies be tested for RSV?

Not always. Testing is most useful when the result will affect management, cohorting, infection control, or diagnostic clarity. Molecular tests, such as PCR, are generally more sensitive than antigen tests.  

How can babies be protected from severe RSV?

The CDC recommends that infants be protected either through maternal RSV vaccination during pregnancy or through infant immunization with a long-acting monoclonal antibody. Most infants do not need both.  

How long are babies contagious with RSV?

People with RSV are generally contagious for three to eight days, but some infants may continue spreading RSV for four weeks or longer.